No products in the cart.
Delaying pegfilgrastim administration reduces bone pain in breast cancer patients
1. In this randomized controlled trial, administering pegfilgrastim 72 hours after chemotherapy reduced bone pain compared with 24- or 48-hour dosing in women with stage I–III breast cancer.
2. Patients in the 72-hour group were less likely to experience bone pain, required rescue analgesics less frequently, and maintained quality of life (QoL) throughout treatment.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Current guidelines recommend prophylactic granulocyte colony-stimulating factors (G-CSFs), such as pegfilgrastim, for patients with breast cancer receiving chemotherapy who are at risk of febrile neutropenia (FN). However, pegfilgrastim is commonly associated with pegfilgrastim-induced bone pain (PIBP), a frequent and often difficult-to-manage adverse effect. This study evaluated whether the timing of pegfilgrastim administration influences the severity of PIBP. In a cohort of 159 patients with stage I–III breast cancer, the mean area under the curve (AUC) for worst daily bone pain over 5 days was lowest among those who received pegfilgrastim 72 hours after chemotherapy, compared with 24 or 48 hours. Although pain scores declined across all groups over successive chemotherapy cycles, the 72-hour group consistently demonstrated greater reductions. Patients in the 72-hour group also experienced lower rates of bone pain, required less rescue analgesia, and did not report clinically meaningful worsening of pain. In addition, quality of life was maintained in this group, whereas it declined significantly in the 24- and 48-hour groups. No cases of FN were reported, and adverse event rates were similar across groups. The study’s generalizability is limited by its single-center design, modest sample size, and lack of blinding. Nonetheless, delaying pegfilgrastim administration to 72 hours post-chemotherapy was associated with reduced bone pain without compromising safety or quality of life, suggesting a simple strategy to improve patient experience during treatment.
Click to read this study in AIM
In-Depth [randomized controlled trial]: This phase 3 randomized controlled trial evaluated whether the timing of pegfilgrastim administration affects pegfilgrastim-induced bone pain (PIBP). Eligible participants were adults aged 18–70 years with stage I–III breast cancer initiating high- or intermediate-risk chemotherapy for febrile neutropenia (FN). Patients with prior chemotherapy, baseline bone pain, or chronic analgesic use were excluded. A total of 159 patients were randomized (n = 53 per group) to receive pegfilgrastim at 24, 48, or 72 hours post-chemotherapy. The primary outcome was the area under the curve (AUC; range 0–40) for worst bone pain over 5 days during cycle 1. Secondary outcomes included pain incidence and duration, rescue analgesic use, quality of life (QoL), and safety outcomes across four cycles. In cycle 1, mean AUC pain scores were significantly lower in the 72-hour group (6.05) compared with the 24-hour (12.74) and 48-hour (14.20) groups (p < 0.001 for both). This reduction persisted across subsequent cycles. The 72-hour group also had consistently lower rates of any-grade and severe bone pain, shorter pain duration in select cycles, and markedly reduced use of rescue analgesia (1.9% vs. 28.3% and 22.6% in the 24- and 48-hour groups, respectively). Quality of life was maintained in the 72-hour group, while clinically meaningful declines and worsening pain were observed in the 24- and 48-hour groups. No significant differences were seen in neutropenia rates, and no cases of FN occurred. Adverse event rates were similar across all groups. Overall, administering pegfilgrastim 72 hours after chemotherapy significantly reduced bone pain and analgesic use without compromising safety or QoL, compared with administration at 24 or 48 hours.
Image: PD
©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
RelatedReports
